Lurasidone Hydrochloride

Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy. The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits. Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objective, real-time biomarker stream for clinicians. The integration is expected to double patient success rates by enabling timely "recapture" interventions — such as maintenance ketamine or TMS sessions — the moment early relapse signals are detected. Patients gain real-time mood, and activity insights through the Emobot app, with automatic notifications and in-app appointment scheduling if relapse risk is flagged. SARASOTA, Fla. and PARIS, March 30, 2026 (GLOBE NEWSWIRE) -- Hope Therapeutics, Inc. (“Hope”), a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced a strategic partnership with Emobot Health to deploy its revolutionary AI-driven emotional monitoring platform across Hope’s rapidly expanding network of interventional psychiatry clinics. This roll-out represents the first large-scale clinical integration of Emobot’s "Depression Thermometer," a passive monitoring tool designed to detect early treatment response and prevent relapse in patients with Treatment-Resistant Depression (TRD). Emobot’s technology replaces cumbersome psychometric questionnaires with a background application on the user’s smartphone to passively and automatically measure levels of depression and potentially suicidality and PTSD. In recent years, there has been widespread recognition that neuroplastic therapies, including potentially IV Ketamine, SPRAVATO® (esketamine), and Transcranial Magnetic Stimulation (TMS) have the potential to replace an older and less effective generation of oral antidepressants. While these modern interventions are enormously promising with reported response rates nearing 90% the industry faces a significant "blind spot": in that approximately 50% of patients relapse within 6 to 12 months. These relapses are often undetected between visits, leading to lost progress and a disconnect between the patient and their care team. “Precision medicine requires real-time data to be effective,” said Jonathan Javitt, M.D., M.P.H., Founder and CEO of Hope Therapeutics . “In psychiatry, the period between clinic visits has traditionally been a ‘blind spot.’ Emobot’s 100% passive, multimodal AI provides us with a continuous stream of objective biomarkers—effectively a ‘360-degree view’ of a patient’s emotional state. We believe this is the new gold standard for care; in fact, we expect every patient to be on Emobot. Our team has 15+ years of experience in supporting digital health applications of this nature, having developed the first cellular-enabled medical device for monitoring of diabetes.” The Emobot platform operates seamlessly in the background of a patient's digital life, utilizing affective computing to analyze facial expressions, vocal tones, and actigraphy. For clinics, this capability is expected to double patient success rates by enabling "recapture" interventions—such as maintenance or booster sessions—the moment a potential relapse is detected. Preliminary evidence from a pooled analysis of three prospective studies (EMC1, EMC2-FR and EMC2-BD) demonstrates strong convergent validity. This post-hoc validation is detailed in a recent preprint (Perzo, A., Petelot, T., Seguier, R., & Magaraggia, I., 2026), Clinical validation of the EMOCARE-derived depressive symptom severity score using established clinician- and self-reported scales: Preliminary evidence across 3 prospective studies, . In this analysis, the technology showed a strong within-person concordance (r=0.89,p< .05) with the MADRS scale and high sensitivity to change (r=0.83, p<.001) relative to PHQ-9 scores. These findings serve as a clinical foundation while the medical community awaits the conclusion of ongoing trials to publish final top-line results. Beyond clinical oversight, the partnership prioritizes patient empowerment through mood self-monitoring. The Emobot app provides patients with real-time insights into their own mood trends, sleep, and physical activity. This transparency allows patients to become active participants in their recovery, using objective data to understand their triggers and progress. If a relapse is detected, the app can trigger automatic notifications directly to the patient, allowing them to instantly reschedule a consultation in-app to get back on track before a crisis occurs. “We are thrilled to join forces with Hope Therapeutics and to launch Emobot in HOPE’s Florida clinics,” said Tanel Petelot, CEO of Emobot. “Hope’s commitment to rapid-acting neuroplastic therapies perfectly aligns with our mission to provide the objective data needed to optimize those very treatments. Together, we are eliminating the guesswork from mental health care.” About Emobot Health Emobot ( ) is a MedTech pioneer based at the Paris Brain Institute (ICM) that has developed the world’s first passive, multimodal AI platform for automated depression assessment and relapse detection. Unlike traditional active monitoring that requires patient interaction, Emobot’s "Depression Thermometer" runs 100% seamlessly in the background, providing clinicians with real-time insights into mood, sleep, and physical activity. Emobot is a trusted partner for leading academic institutions, including UC San Diego, Yale University, Johns Hopkins. Media Contact: Tanel Petelot, CEO, press@emobot.fr About Hope Therapeutics, Inc. Hope Therapeutics ( ),Inc., a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company building a nationwide network of interventional psychiatry clinics. Hope specializes in treating the toughest mental health conditions—including suicidal depression, PTSD, and TRD—using neuroplastic therapies such as IV Ketamine, Transcranial Magnetic Stimulation (TMS), and Hyperbaric Oxygen Therapy. With a goal to offer integrated care within driving distance of every American by the end of 2026. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. ( ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com

🔥【通用名称】二甲双胍维格列汀 【日文名称】エクメット配合錠HD【英文名称】Metformin Hydrochloride and Vildagliptin Tablets【适应症】适用于成人2型糖尿病患者：本品配合饮食和运动治疗，用于二甲双胍单药治疗达最大耐受剂量血糖仍控制不佳或正在接受维格列汀与二甲双胍联合治疗。当稳定剂量的胰岛素联合二甲双胍治疗血糖仍控制不佳时，本品可与胰岛素联合使用，配合饮食和运动治疗，改善血糖控制。 【双向2型糖尿病治疗】🔥选择性DPP-4抑制剂➕双胍组合药物该药是维格列汀和盐酸二甲双胍的复方药。<维格列汀>通过选择性、可逆地抑制DPP-4，增加内源性GLP-1的浓度，以血糖依赖的方式促进胰岛素分泌，抑制胰高血糖素分泌，发挥降血糖作用。<盐酸二甲双胍>它主要抑制肝脏中的糖异生并发挥降血糖作用，而不介导胰腺β细胞的胰岛素分泌。还已知具有促进外周的糖摄取和抑制肠道的糖吸收等作用。DPP-4抑制作用Vildagliptin 以浓度依赖性方式抑制人血浆DPP-4，IC50值为2.7nM。此外，维格列汀对人DPP-4（重组）具有高亲和力，Ki值为2～3nM。2型糖尿病患者重复口服维格列汀50mg，每天2次，持续7天，可增加血浆GLP-1水平。 🔥HD盐酸维格列汀二甲双胍组合片适应症或作用：2型糖尿病仅限于维格列汀和盐酸二甲双胍联合治疗。 用法用量：Equmet 复合片 HD一般情况下，成人每次 1 片（50mg/500mg 维格列汀/盐酸二甲双胍）口服，每天两次，早晚各一次。 エクメット配合錠HD100錠/盒日本🇯🇵 医院推荐治疗||型糖尿病用药。对于二甲双胍或武田老糖/小糖、金丝雀等不能达到最佳治疗效果的，选择クメット配合錠HD。产品特点：维格列汀为高选择性底物样DPP-4酶抑制剂，以其独特的葡萄糖浓度依赖性胰岛α、β细胞双调节效应，与其他口服降糖药(磺脲类、噻唑烷二酮类)相比具有降糖效果相当，但低血糖风险显著较低，且不增加患者体重之优势。クメット配合錠为治疗||型糖尿病的理想之选。1.根据血糖值促进胰岛素分泌2.抑制肝脏产糖，促进肌肉中糖的利用3.改善血糖控制 利格列汀片属于DPP-4抑制剂，这是一种新型的口服降糖药物，主要通过抑制二肽基肽酶4(DPP-4)的活性，减少肠促胰岛素的降解，从而增加胰岛素的分泌并降低胰高血糖素的水平，发挥降糖作用。那么利格列汀在使用上需要注意哪些问题呢?大家快随我来看一看吧! 一、适用于哪些人群? 本品适用于治疗2型糖尿病。单药治疗本品作为饮食控制和运动的辅助治疗，用于改善2型糖尿病患者的血糖控制。与盐酸二甲双胍联合使用当单独使用盐酸二甲双胍仍不能有效控制血糖时，本品可与盐酸二甲双胍联合使用，在饮食和运动基础上改善2型糖尿病患者的血糖控制。与盐酸二甲双胍和磺脲类药物联合使用当盐酸二甲双胍和磺脲类药物联合使用仍不能有效控制血糖时，本品可与盐酸二甲双胍和磺脲类药物联合使用，在饮食和运动基础上改善 1、特殊人群： (1)肾功能不全患者：肾功能不全患者不需要调整剂量。 (2)肝功能不全患者：肝功能不全患者不需要调整剂量。 2、漏服：如果遗漏给药，建议患者在下次服药时不需服用双倍剂量。 二、不良反应 在起效的同时，利格列汀片也可能会对病人造成一些不良的状况，比如鼻咽炎、低血糖是比较常见的，但也有一些病人会发生高敏反应，比如荨麻疹、血管性水肿和肌肉疼痛等。少数病人还可能会出现低血糖，特别是当服用的剂量比较大，或是联合其他的药物一起用的时候，低血糖会比较严重一些。 三、药物相互作用 已知促胰岛素分泌药和胰岛素会引起低血糖。在一项临床试验中，利格列汀与促胰岛素分泌药(例如，磺脲类)合用引起的低血糖发生率，高于安慰剂。在重度肾功能不全患者中利格列汀与胰岛素合用会引起较高的低血糖的发生率。因此，与利格列汀合用时，需要较低剂量的促胰岛素分泌药或胰岛素，从而减少低血糖的风险。 四、药品禁忌以及注意事项 1.禁用于对利格列汀有过敏史，诸如荨麻疹、血管性水肿或支气管高敏反应的患者。 2.本品不能用于治疗1型糖尿病患者，也不能用于治疗糖尿病性酮症酸中毒。 更多详情请查阅日文使用说明书 大日本住友制药（Sumitomo Pharma）——▫️ 创立时间：1897年（大阪，原住友铜业制药部门）▫️ 母公司：日本四大财团之一的住友集团▫️ 核心转型：从传统制药到基因/细胞治疗 📜百年创新之路1897-1945：→ 为住友铜矿生产消毒剂和创伤药1980s：→ 独立运营，专注中枢神经药物2022年：→ 57亿美元收购Myovant Sciences，进军女性健康领域2023年：→ 与京都大学合作CAR-T疗法获批临床 🧬四大技术支柱▫️ 精神神经领域：→ 抗精神病药Latuda®（年销超20亿美元）→ 抑郁症新药Rexulti®▫️ 细胞基因治疗：→ 与京都大学开发实体瘤CAR-T→ 干细胞治疗帕金森病▫️ 女性健康：→ 子宫肌瘤新药Myfembree®▫️ 传统优势：→ 百年消毒技术开发新型抗菌剂 💡冷知识暴击• 大阪总部保存着明治时期铜矿消毒剂配方📜• 实验室用AI分析精神病患者脑电波数据🧠• 新冠期间开发出长效消毒喷雾技术• 仍遵守住友集团"不追求暴利"的家训 🌍全球布局• 波士顿基因治疗研究中心（专注AAV载体）• 中国苏州建精神类药物生产基地• 与武田合作开发神经退行性疾病药物 📢企业理念"矿工精神"转型"生命科学"：→ 连续10年研发投入超营收25%→ 入选"日本最佳职场"数据来源：住友年报/《日本医药创新史》 往期精彩内容查阅📖👇 二甲双胍是餐前吃？餐后吃？其适应症、用法用量及注意事项都有哪些？ 对于2型糖尿病降糖与体重管理减肥，替尔泊肽与司美格鲁肽哪个更显著？ 日本武田长效降糖药使用说明书：武田老糖（曲格列汀）优势在哪？使用方法和注意事项 长期失眠对人的危害有多严重？当身体发出以下“求救信号”时，绝对不能再熬夜了 二型糖尿病：金丝雀（曲格列汀和卡格列净搭配，摆脱注射胰岛素） 【视频说明】日本久光贴40mg与100mg有哪些区别？如何辨别真假？ 日药利马前列素片：改善腰椎管狭窄症状，“腰椎间盘突出症升级版” 【健康科普】风湿性关节炎与类风湿关节炎，这两者是完全不同的疾病 骨科特效：类风湿，关节炎，肩周炎，内风湿，强直性脊柱炎，颈椎腰椎，腰腿疼痛等风湿骨病用药 【再生医疗】NK-EXO免疫细胞外泌体（NK-Exos）在疾病诊断、再生医学、抗衰修复等前沿领域的研究与应用 180款日本医院诊所药局药妆店常见的医药健康产品大全 【使用说明】ES-玻利他命（ESポリタミン配合顆粒） 润生堂天地苁蓉：滋阴补阳、提精壮气、抗衰老、缓解更年期症状…… NAD+有哪些作用？为什么要补充NAD+？ 日本人常用三款降压药的区别与选择要点：东和降压氨氯地平片/辉瑞依普利酮高级降压/第一三共奥美沙坦酯&阿折地平HD高级降压 抗癌特效药替吉奥、盐酸阿拉莫林片Anamorelin使用说明，用法用量及副作用注意事项 抗恶性肿瘤产品新型靶向治疗药物使用说明、用法用量及副作用注意事项 日本再生医疗PureStem品牌历史及干细胞上清液、NMN、NAD+产品系列 文章用于交流学习，用药谨遵医嘱！ 免责声明：图文转自网络，不代表本平台立场，仅供读者交流学习，著作权属归原创者所有。如有侵权，请在后台留言联系我们进行删除，谢谢！  10年口碑服务 高端国际医疗与大健康咨询服务 交流咨询V信：S2108885166 整理不易，记得点赞收藏